Caroline Soliman

Caroline Soliman

Auto-generated profile, based on publicly available information

Caroline Soliman

Peter Doherty Institute for Infection and Immunity, The University of Melbourne 2 Department of Microbiology & Immunology Melbourne

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CSCaroline Soliman
Caroline Soliman
SESarah Eastwood
Sarah Eastwood
Truong Vi KhanhTruong Vi Khanh
Truong Vi Khanh
PRPaul A Ramsland
Paul A Ramsland
Aaron ElbourneAaron Elbourne
Aaron Elbourne
The cytotoxic effects of melittin, a bee-venom peptide, have been widely studied towards cancer cells. Typically, these studies have examined the effect of melittin over extended-time courses (6–24 hours), meaning that immediate cellular interactions have been overlooked. In this work, we demonstrate the rapid effects of melittin on both gastric and colorectal cancer, specifically AGS, COLO205 and HCT-15 cell lines, over a period of 15 minutes. Melittin exhibited a dose dependent effect at 4 hours of treatment, with complete cellular death occurring at the highest dose of 20 μg/mL. Interestingly, when observed at shorter time points, melittin induced cellular changes within seconds; membrane damage was observed as swelling, breakage or blebbing. High-resolution imaging revealed treated cells to be compromised, showing clear change in cellular morphology. After 1 minute of melittin treatment, membrane changes were observed, and intracellular material could be seen expelled from the cells. Overall, these results enhance our understanding of the fast acting anti-cancer effects of melittin.

1 April 2018 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
CSCaroline Soliman
Caroline Soliman
Anna Katrina WalduckAnna Katrina Walduck
Anna Katrina Walduck
EYElizabeth Yuriev
Elizabeth Yuriev
JRJack S. Richards
Jack S. Richards
CCColette Cywes-Bentley
Colette Cywes-Bentley
PRPaul A Ramsland
Paul A Ramsland
In response to the widespread emergence of antibiotic-resistant microbes, new therapeutic agents are required for many human pathogens. A non-mammalian polysaccharide, poly-N-acetyl-D-glucosamine (PNAG), is produced by bacteria, fungi, and protozoan parasites. Antibodies that bind to PNAG and its deacetylated form (dPNAG) exhibit promising in vitro and in vivo activities against many microbes. A human IgG1 mAb (F598) that binds both PNAG and dPNAG has opsonic and protective activities against multiple microbial pathogens and is undergoing preclinical and clinical assessments as a broad-spectrum antimicrobial therapy. Here, to understand how F598 targets PNAG, we determined crystal structures of the unliganded F598 antigen-binding fragment (Fab) and its complexes with N-acetyl-D-glucosamine (GlcNAc) and a PNAG oligosaccharide. We found that F598 recognizes PNAG through a large groove-shaped binding site that traverses the entire light- and heavy-chain interface and accommodates at least five GlcNAc residues. The Fab–GlcNAc complex revealed a deep binding pocket in which the monosaccharide and a core GlcNAc of the oligosaccharide were almost identically positioned, suggesting an anchored binding mechanism of PNAG by F598. The Fab used in our structural analyses retained binding to PNAG on the surface of an antibiotic-resistant, biofilm-forming strain of Staphylococcus aureus. Additionally, a model of intact F598 binding to two pentasaccharide epitopes indicates that the Fab arms can span at least 40 GlcNAc residues on an extended PNAG chain. Our findings unravel the structural basis for F598 binding to PNAG on microbial surfaces and biofilms.

1 June 2017 in Current Opinion in Structural Biology
Verified
Journal Article
Closed access
CSCaroline Soliman
Caroline Soliman
EYElizabeth Yuriev
Elizabeth Yuriev
PRPaul A Ramsland
Paul A Ramsland

1 June 2020 in Current Opinion in Structural Biology
Verified
Journal Article
Closed access
CSCaroline Soliman
Caroline Soliman
GPGerald B Pier
Gerald B Pier
PRPaul A Ramsland
Paul A Ramsland

12 December 2019 in Journal of Biological Chemistry
Verified
Journal Article
Closed access
PDF file
CSCaroline Soliman
Caroline Soliman
JCJia Xin Chua
Jia Xin Chua
MVMireille Vankemmelbeke
Mireille Vankemmelbeke
RMRichard S. McIntosh
Richard S. McIntosh
AGAndrew J. Guy
Andrew J. Guy
PRPaul A Ramsland
Paul A Ramsland

10 September 2020 in Biochemical Journal
Verified
Journal Article
Open access
PDF file
CSCaroline Soliman
Caroline Soliman
AGAndrew J. Guy
Andrew J. Guy
JCJiaxin Chua
Jiaxin Chua
MVMireille Vankemmelbeke
Mireille Vankemmelbeke
RMRichard S. McIntosh
Richard S. McIntosh
PRPaul A Ramsland
Paul A Ramsland
Immunotherapy has been successful in treating many tumour types. The development of additional tumour-antigen binding monoclonal antibodies (mAbs) will help expand the range of immunotherapeutic targets. Lewis histo-blood group and related glycans are overexpressed on many carcinomas, including those of the colon, lung, breast, prostate and ovary, and can therefore be selectively targeted by mAbs. Here we examine the molecular and structural basis for recognition of extended Lea and Lexcontaining glycans by a chimeric mAb. Both the murine (FG88.2) IgG3 and a chimeric (ch88.2) IgG1 mAb variants showed reactivity to colorectal cancer cells leading to significantly reduced cell viability. We determined the X-ray structure of the unliganded ch88.2 fragment antigen-binding (Fab) containing two Fabs in the unit cell. A combination of molecular docking, glycan grafting and molecular dynamics simulations predicts two distinct subsites for recognition of Lea and Lex trisaccharides. While light chain residues were exclusively used for Lea binding, recognition of Lex involved both light and heavy chain residues. An extended groove is predicted to accommodate the Lea-Lex hexasaccharide with adjoining subsites for each trisaccharide. The molecular and structural details of the ch88.2 mAb presented here provide insight into its cross-reactivity for various Lea and Lexcontaining glycans. Furthermore, the predicted interactions with extended epitopes likely explains the selectivity of this antibody for targeting Lewis-positive tumours.